z-logo
open-access-imgOpen Access
Intravenous Immunoglobulin Therapy for Pure Red Cell Aplasia Related to Human Parvovirus B19 Infection: A Retrospective Study of 10 Patients and Review of the Literature
Author(s) -
Yoann Crabol,
Benjamin Terrier,
Flore Rozenberg,
Vincent Pestre,
C. Legendre,
Olivier Hermine,
C. Montagnier-Petrissans,
Loïc Guillevin,
Luc Mouthon,
G. Loic,
B. Annette,
F. Alain,
Frédèric Bertrand,
Guillaume Bertrand,
Amelie Lupp,
I. Lamy,
M. Phelan Catherine,
M. Luc,
O. Eric,
Palmieri Nathalie,
S. Helene,
S. Tarek,
P. Hopital Ambroise,
Lefebvre Jean-Marie,
Francisco Bruno,
C. Bernard,
P. Thomas,
D. Francois,
Muhammed Emin Zora,
H. Olivier,
L. Christophe,
Laure Philippe,
L Olivier,
P.-Y. Jean-Charles,
G. Norbert-Claude,
JeanPaul Fouché,
Laurent Guy,
B. Hopital,
N. Hopital,
Amina Barkat
Publication year - 2012
Publication title -
clinical infectious diseases
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.44
H-Index - 336
eISSN - 1537-6591
pISSN - 1058-4838
DOI - 10.1093/cid/cis1046
Subject(s) - medicine , pure red cell aplasia , parvovirus , anemia , retrospective cohort study , gastroenterology , antibody , hemoglobin , surgery , immunology , virus
We evaluated the efficacy of intravenous immunoglobulin (IVIG) therapy in patients with pure red cell aplasia (PRCA) related to human parvovirus B19 (HPV-B19) infection.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom